Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institutions experience

Conclusions Pertuzumab, trastuzumab, and taxane therapy seems to confer progression-free survival benefit for previously treated metastatic breast cancer. The use of the dual anti-HER2 antibodies, pertuzumab and trastuzumab, in addition to cytotoxic chemotherapy agents for previously treated metastatic breast cancer should be further evaluated.

http://opp.sagepub.com/cgi/content/abstract/22/2/261?rss=1

Source: Journal of Oncology Pharmacy Practice - February 27, 2016 Category: Cancer & Oncology Authors: Dao, B. D., Ho, H., Quintal, L. N. Tags: Original Articles Source Type: research